In the present study, we found that the expression of IL-4, IL-6, TNF-α, and IFN-γ but not IL-10 dramatically increased after T cell interaction with peptides+HB100-108/pulsed DCs, indicating that this vaccine design has the ability to activate allogeneic T cells against tumor antigen. The gene discussed is IL10; the disease is neoplasm.